Nektar Therapeutics (NKTR)

51.87
0.98 1.90
NASDAQ : Health Technology
Prev Close 52.85
Open 52.85
Day Low/High 50.86 / 53.73
52 Wk Low/High 17.51 / 111.36
Volume 3.20M
Avg Volume 3.69M
Exchange NASDAQ
Shares Outstanding 171.40M
Market Cap 9.57B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

New Data For NKTR-181, A First-in-Class Investigational Opioid To Treat Chronic Low Back Pain In Adult Patients New To Opioid Therapy, Presented At College On Problems Of Drug Dependence 80th Annual Scientific Meeting

New Data For NKTR-181, A First-in-Class Investigational Opioid To Treat Chronic Low Back Pain In Adult Patients New To Opioid Therapy, Presented At College On Problems Of Drug Dependence 80th Annual Scientific Meeting

SAN FRANCISCO, June 14, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug...

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Jim Cramer says the tech titans are leading the way, but out side of the tech sector, very few stocks are following.

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hasbro, Dropbox, Carlyle Group, Corning, Banco Santander, Goldman Sachs, Edwards Lifesciences, J. Jill and more.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

Nektar To Webcast Presentation At The Jefferies 2018 Healthcare Conference In New York

Nektar To Webcast Presentation At The Jefferies 2018 Healthcare Conference In New York

SAN FRANCISCO, June 5, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

Preliminary Data For NKTR-214 In Combination With Opdivo (nivolumab) For Patients With Stage IV Metastatic Melanoma, Renal Cell Carcinoma, And Urothelial Cancers Presented At ASCO 2018

Preliminary Data For NKTR-214 In Combination With Opdivo (nivolumab) For Patients With Stage IV Metastatic Melanoma, Renal Cell Carcinoma, And Urothelial Cancers Presented At ASCO 2018

Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation

Nektar Therapeutics Announces Six Abstracts Accepted For Presentation At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.

Nektar Therapeutics Moves Up In Analyst Rankings, Passing Thermo Fisher Scientific

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #12 spot from Thermo Fisher Scientific Inc , according to ETF Channel. Below is a chart of Nektar Therapeutics versus Thermo Fisher Scientific Inc plotting their respective rank within the S&P 500 over time (NKTR plotted in blue; TMO plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

New Oncology Clinical Collaboration Between Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-biased Agonist, And TAK-659, A Dual SYK And FLT-3 Inhibitor, In Liquid And Solid Tumors

New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms

GE and Kohl's Are Among 2 Stocks Poised For Reversal

GE and Kohl's Are Among 2 Stocks Poised For Reversal

These names are showing bullish and bearish technical patterns over the past week.

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Stocks finished higher on Wednesday.

Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

It is premature to think that this market has hit a top until there is further evidence in the price action.

Next Week Could Be Confusing

Many summer winners are in correction mode.

TheStreet Quant Rating: D (Sell)